Erytech Pharma S.A.: ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
Events required to trigger interim superiority analysis accrued
Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021
LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) ERYTECH Pharma (Nasdaq & Euronext: ERYP),
a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer.
TRYbeCA-1, the pivotal Phase 3 clinical trial evaluating ERYTECH s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has completed patient enrollment. A total of 510 patients participated in the trial, slightly above the target enrollment of 482 patients.